Drug profile · INN
lifileucel
AMTAGVI
lifileucel (AMTAGVI) is a somatic cell supplemental therapy. Associated with Iovance Biotherapeutics B.V..
EMA: application withdrawn Antineoplastic and immunomodulating agents (L01) L01XL11
Patents linked 3
Pipeline programs 8
News articles 0
Drug details — lifileucel
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- —
- Patents
- 3
- Programs
- 8
- Data quality
- 0.89
Quick answer
lifileucel (AMTAGVI) is a somatic cell supplemental therapy. Associated with Iovance Biotherapeutics B.V..
Key facts
INN lifileucel
Brand AMTAGVI
Mechanism Somatic cell supplemental therapy
Therapeutic class Antineoplastic and immunomodulating agents (L01)
ATC code L01XL11
Originator Iovance Biotherapeutics B.V.
Mechanism of action
Somatic cell supplemental therapy
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | application withdrawn | — |
Pipeline programs
Related & competitor drugs
Related patents
Frequently asked questions
What is lifileucel?
lifileucel (AMTAGVI) is a somatic cell supplemental therapy. Associated with Iovance Biotherapeutics B.V..
What is the brand name for lifileucel?
AMTAGVI is a marketed brand name for lifileucel. Check FDA Drugs@FDA for the current US label holder and prescribing information.